Interaction of St John's wort with low-dose oral contraceptive therapy: A randomized controlled trial

British Journal of Clinical Pharmacology

Volumn 56, Issue 6, 2003, Pages 683-690

  Pfrunder, Arabelle ^a   Schiesser, Monika ^a   Gerber, Simone ^a   Haschke, Manuel ^a   Bitzer, Johannes ^a   Drewe, Juergen ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Cytochromes; Drug effects; Interaction; Oral contraceptives; P glycoprotein; Pharmacokinetics; St john's wort

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL; ETONOGESTREL; HYPERICUM PERFORATUM EXTRACT; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MAXIMUM ALLOWABLE CONCENTRATION; MENSTRUAL CYCLE; NORMAL HUMAN; OVARY FOLLICLE MATURATION; OVARY FUNCTION; OVULATION; PREGNANCY; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION;

ADULT; CONTRACEPTIVES, ORAL; CONTRACEPTIVES, ORAL, SYNTHETIC; DESOGESTREL; DRUG INTERACTIONS; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; HYPERICUM; OVARY; PHYTOTHERAPY; PLANT EXTRACTS; UTERINE HEMORRHAGE;

EID: 0344081240     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.02005.x     Document Type: Article

References (35)

1. Linde K, Melchart D, Mulrow CD, Berner M. St John's wort and depression. JAMA 2002; 288: 447-448; discussion 448-449.
2. Gaster B, Holroyd J. St John's wort for depression: a systematic review. Arch Intern Med 2000; 160: 152-156.
3. Williams JW Jr, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharniacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132: 743-756.
4. Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung 1999; 49: 289-296.
5. Vorbach EU, Hubner WD, Arnoldt KH. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. J Geriatr Psychiatry Neurol 1994; 7(Suppl 1): S19-S23.
6. Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. Br Med J 2000; 321: 536-539.
7. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Br Med J 1999; 319: 1534-1538.
8. Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000; 15: 61-68.
9. Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998; 54: 589-594.
10. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355 (9203): 548-549.
11. Mai I, Kruger H, Budde K, Johne A, Brockmoller J, Neumayer HH, et al. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000; 38: 500-502.
12. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John's wort and cyclosporine. Ann Pharmacother 2000; 34: 1013-1016.
13. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 338-345.
14. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort [letter]. Lancet 2000; 355: 547-548.
15. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604.
16. Perloff MD, von Moltke LL, Stornier E, Shader RI, Greenblatt DJ. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001; 134: 1601-1608.
17. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002; 53: 75-82.
18. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000; 67: 451-457.
19. Ernst E. Second thoughts about safety of St John's wort. Lancet 1999; 354: 2014-2016.
20. Rätz AE, von Moos M, Drewe J. Johanniskraut: ein Phytopharmakon mit potentiell gefährlichen Interaktionen. Schweiz Rundsch Med Prax 2001; 90: 843-849.
21. Schwarz UI, Buschel B, Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol 2003; 55: 112-113.
22. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349-356.
23. Gorski JC, Hamman MA, Wang Z, Vasavada N, Huang S, Hall SD. The effect of St John's wort on the efficacy of oral contraception. Clin Pharmacol Ther 2002; 71: P25.
24. CPMP Working Party on Efficacy of Medicinal Products. EEC note for guidance: good clinical practice for trials on medicinal products in the European Community. Pharmacol Toxicol 1990; 67: 361-372.
25. Gentile DM, Verhoeven CH, Shimada T, Back DJ. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther 1998; 287: 975-982.
26. Hasenack HG, Bosch AM, Kaar K. Serum levels of 3-keto-desogestrel after oral administration of desogestrel and 3-keto-desogestrel. Contraception 1986; 33: 591-596.
27. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Stockholm, Sweden: Swedish Pharmaceutcal Press, 2000.
28. Endrikat J, Cronin M, Gerlinger C, Ruebig A, Schmidt W, Dusterberg B. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. Contraception 2001; 64: 201-207.
29. Rosenberg MJ, Waugh MS, Higgins JE. The effect of desogestrel, gestodene, and other factors on spotting and bleeding. Contraception 1996; 53: 85-90.
30. Barditch-Crovo P, Trapnell CB, Ette E, Zacur HA, Coresh J, Rocco LE, et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther 1999; 65: 428-438.
31. Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40: 783-787.
32. Li AP, Hartman NR, Lu C, Collins JM, Strong JM. Effects of cytochrome P450 inducers on 17α-ethinyloestradiol (EE2) conjugation by primary human hepatocytes. Br J Clin Pharmacol 1999; 48: 733-742.
33. Guengerich FP. Metabolism of 17 alpha-ethynylestradiol in humans. Life Sci 1990; 47: 1981-1988.
34. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294: 88-95.
35. Wurglics M, Westerhoff K, Holoubek G, Schubert M, Mueller W. Aktuelle Johanniskrautforschung. Deutsche Apothekerzeitung 2002; 142: 1153-1175.